Systemic Therapy for Sjögren Closer With Phase 3 Success

by Medscape • 2025/11/03 • 0 Comments

Current treatment options have been limited to symptom control. Telitacicept, a novel fusion protein, and ianalumab, a monoclonal antibody, demonstrate improvement in disease activity.
Medscape Medical News

← Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Pediatrics board breaks down rise in vernal keratoconjunctivitis cases →

Post navigation